Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2021 February;40(1) > International Angiology 2021 February;40(1):42-51

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  PERIPHERAL ARTERIAL DISEASE Editor’s choice • Freefree

International Angiology 2021 February;40(1):42-51

DOI: 10.23736/S0392-9590.20.04462-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

A systematic review and meta-analysis of bioresorbable vascular scaffolds for below-the-knee arterial disease

Jetty IPEMA 1 , Steven KUM 2, Eline HUIZING 1, Michiel A. SCHREVE 1, Ramon L. VARCOE 3, 4, 5, Constantijn E. HAZENBERG 6, Jean-Paul DE VRIES 7, Çağdaş ÜNLÜ 1

1 Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands; 2 Department of Surgery, Changi General Hospital, Singapore, Singapore; 3 Department of Surgery, Prince of Wales Hospital, Sydney, Australia; 4 Faculty of Medicine, University of New South Wales, Sydney, Australia; 5 The Vascular Institute, Prince of Wales Hospital, Sydney, Australia; 6 Department of Vascular Surgery, University Medical Center (UMC) Utrecht, Utrecht, the Netherlands; 7 Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen (UMCG), Groningen, the Netherlands



INTRODUCTION: Different types of bioresorbable vascular scaffolds (BVSs) have been developed and used in below-the-knee (BTK) arterial diseases. This is the first study reviewing and analyzing the literature on BVS treatment for BTK arterial disease.
EVIDENCE ACQUISITION: MEDLINE, Embase, and Cochrane were searched for studies published until October 21, 2019. The search, study selection, quality assessment, and data extraction were performed by 2 authors independently. Articles that studied the treatment of BTK arterial disease by using BVSs were eligible. Exclusion criteria were studies with a variant design (e.g. case reports <5 patients), non-BTK indications for BVS use, and nonhuman studies. Primary endpoint was 12-month primary patency. Secondary endpoints were 12-month freedom from clinically driven target lesion revascularization (CD-TLR), limb salvage, survival, and amputation-free survival (AFS). Study quality was assessed by the Methodological Index for Non-randomized Studies score.
EVIDENCE SYNTHESIS: Five studies representing 155 patients with 160 treated limbs met the inclusion criteria. Pooled 12-month primary patency per limb was 90% (143/160; 95% confidence interval [CI]: 0.84-0.95), freedom from CD-TLR 96% (124/130; 95% CI: 0.91-0.99), limb salvage rate 97% (156/160; 95% CI: 0.94-1.00), survival rate 90% (112/125; 95% CI: 0.82-0.96), and AFS rate 89% (110/125; 95% CI: 0.81-0.94). Subgroup analyses of included Absorb BVS studies showed similar results. All studies were assessed as moderate quality.
CONCLUSIONS: This meta-analysis of case series showed good 12-month patency and clinical results with BVSs for BTK arterial disease, even in patients with multimorbidity and short but complex lesions. These results encourage a revival of this scaffold.


KEY WORDS: Blood vessels; Ischemia; Arteries; Meta-analysis; Systematic review

inizio pagina